@article{f4cb01fa84fe4b6498a4d9c4a4833628,
title = "Asthma Step-Down Strategies: Perhaps the Patient Should Decide?",
keywords = "Asthma step down",
author = "Brian Lipworth and Elliot Israel",
note = "B. Lipworth has received research support from Teva, Meda, Boehringer Ingelheim, AstraZeneca, Chiesi, Sanofi, Janssen, and Roche; has received consultancy fees from Boehringer, Cipla, Dr Reddys, Sandoz, Chiesi, Teva, and Meda; has received travel support from Teva, Boehringer, Napp, and GlaxoSmithKline; and has a son who is employed by Boehringer Ingelheim. E. Israel has received consultancy fees from AstraZeneca, Philips Respironics, Regeneron Pharmaceuticals, Bird Rock Bio, Novelution Pharmaceuticals, Vitaeris, Sanofi, and Merck; has received consultancy fees from and is a member of the data and safety monitoring board for Novartis; has received travel support from Research in Real Life; has received consultancy fees and travel support from Teva Specialty Pharmaceuticals; and has received research support from Genentech, Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, Teva, and Sanofi.",
year = "2018",
month = mar,
doi = "10.1016/j.jaip.2017.08.026",
language = "English",
volume = "6",
pages = "644--645",
journal = "The Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "American Academy of Allergy, Asthma and Immunology",
number = "2",
}